[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity
Rhythm Pharmaceuticals CFO Hunter C. Smith exercised 3,000 stock options at $17.87 per share, converting them into common stock. This transaction increased his direct holdings to 119,611 shares, with no shares reported as sold. The exercised options were fully vested, indicating a routine conversion of equity compensation.
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock
Christopher German, CAO of Rhythm Pharmaceuticals (NASDAQ:RYTM), sold 4,643 shares of company stock for $428,131 on May 15, 2026, following the exercise of stock options. He acquired 4,442 shares through options at varying prices before the sale, resulting in no direct holdings after the transactions. This comes after the company reported strong Q1 2026 earnings, exceeding revenue expectations, and an increased price target from Stifel.
Rhythm Pharmaceuticals CAO Christopher German sells $428,131 in stock
Rhythm Pharmaceuticals' Chief Accounting Officer, Christopher German, sold 4,643 shares of company common stock for $428,131 on May 15, 2026, after exercising stock options. Following the transactions, Mr. German holds no direct shares in the company. This comes amidst recent stock volatility but also strong Q1 2026 earnings and a raised price target from Stifel due to positive IMCIVREE launch performance.
Rhythm Pharmaceuticals (RYTM) officer sells 4,643 shares after exercising options
Rhythm Pharmaceuticals' Corporate Controller & CAO, Christopher Paul German, exercised stock options for 4,442 shares and subsequently sold 4,643 shares of common stock at an average price of $92.21 per share. This transaction resulted in him holding zero direct common stock shares, though he retains significant stock options from grants in previous years. The filing highlights an insider selling activity following option exercises, with a net sale of 4,643 shares valued at approximately $428,131.
Expanded EU IMCIVREE Label for Hypothalamic Obesity Could Be A Game Changer For Rhythm (RYTM)
Rhythm Pharmaceuticals' IMCIVREE (setmelanotide) recently received expanded EU approval for acquired hypothalamic obesity, bolstering its potential market. Despite this positive development and strong Phase 3 data, the company continues to report net losses and relies on future commercialization success, with ongoing operating losses and R&D spending posing risks of further dilution through capital raises. While analysts hold varied price targets, the expanded label and growth in rare neuroendocrine obesity disorders present a significant opportunity for Rhythm's investment narrative.
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM)
Perceptive-affiliated entities, including Perceptive Advisors and Joseph Edelman, have filed an amended Schedule 13G reporting a combined 5.1% beneficial ownership stake in Rhythm Pharmaceuticals (RYTM). This stake amounts to 3,519,626 shares, calculated based on 68,532,607 shares outstanding as of May 1, 2026, and includes shares held directly and those convertible from Series A Preferred Stock. The filing details shared voting and dispositive power among the affiliated entities and Joseph Edelman.
Rhythm Pharmaceuticals, Inc. - Common Stock (NQ: RYTM
This page provides a collection of headline news articles from Benzinga concerning Rhythm Pharmaceuticals, Inc. (NQ: RYTM) and the broader biotech sector. The articles, primarily from August and September 2021, cover topics such as biotech pulses, stocks reaching 52-week lows, market moving events, and regulatory approvals, including the European approval of Rhythm Pharma's Imcivree. The page also displays real-time stock quotes and provides links for detailed financial information.
RYTM: Strong HO launch, global reach, and next-gen therapies drive growth in rare obesity markets
Rhythm Pharmaceuticals (RYTM) is positioned for growth due to a strong launch of its HO drug, which targets rare genetic and acquired obesity syndromes. The company is developing next-generation therapies to enhance patient convenience and reduce side effects. Additionally, ongoing studies for a potential indication in Prader-Willi syndrome could further expand its market reach.
New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story
Rhythm Pharmaceuticals presented new clinical data for setmelanotide (IMCIVREE) in adults with acquired hypothalamic obesity, showing significant BMI reductions and improved cardiometabolic outcomes. This data, following recent pediatric findings, strengthens the drug's evidence base asIMCIVREE expands its commercial reach in the US and Europe. While the company still reports quarterly losses, these clinical updates support the potential for broader and sustained use, which could impact future financial performance and investor sentiment for RYTM.
Comerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTM
Comerica Bank significantly reduced its holdings in Rhythm Pharmaceuticals by 98.1% in the fourth quarter, selling over 205,000 shares. Despite this large reduction, other hedge funds adjusted their stakes with some increasing their positions. Rhythm Pharmaceuticals reported better-than-expected quarterly results, and while insider selling has occurred, the company maintains a "Moderate Buy" consensus rating from Wall Street analysts.
New Setmelanotide Data Shapes Rhythm Pharmaceuticals Obesity Growth Story
Rhythm Pharmaceuticals presented new clinical data on setmelanotide for acquired hypothalamic obesity, showing significant BMI reductions and improved cardiometabolic outcomes in adults, complementing recent pediatric efficacy results. These findings reinforce the drug's potential across different patient groups following recent regulatory approvals and commercial launches. Despite current quarterly losses, the expanding clinical dataset supports the company's growth narrative and provides key talking points for discussions with physicians and payers.
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
Rhythm Pharmaceuticals announced new data presentations at the 2026 European Congress of Endocrinology, highlighting the efficacy of setmelanotide in treating acquired hypothalamic obesity (HO) and Bardet-Biedl syndrome (BBS). Real-world data showed significant BMI reductions and improved cardiometabolic risk indices in HO patients, while new research underlined the burden and under-recognition of hyperphagia. The presentations emphasize the broad metabolic benefits and potential of setmelanotide as a therapeutic option for these rare neuroendocrine diseases.
Hidden hunger in rare obesity: new UK study finds severe hyperphagia missed
Rhythm Pharmaceuticals presented new data on setmelanotide at the 2026 European Congress of Endocrinology, highlighting its effectiveness in reducing BMI and improving cardiometabolic risk in patients with acquired hypothalamic obesity. A notable UK study revealed that severe hyperphagia in Bardet-Biedl syndrome is significantly underrecognized through self-reported questionnaires, with expert interviews identifying a much higher prevalence. These findings underscore the broad benefits of setmelanotide and the need for improved diagnostic methods for hyperphagia.
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results
Rhythm Pharmaceuticals (RYTM) has seen increased attention following U.S. and European approvals for IMCIVREE and strong first-quarter revenue. The stock is currently trading at $94.17, with a recent 7-day return of 10.04%, and analysts suggest it is undervalued with a fair value of $137.67 based on future growth expectations for IMCIVREE. However, its high Price/Sales ratio of 29.7x, compared to an industry average of 10.3x, signals that significant future growth may already be priced in, posing a risk should regulatory setbacks or slower uptake occur.
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results
Rhythm Pharmaceuticals (RYTM) is under investor scrutiny after recent approvals for IMCIVREE and strong first-quarter results. The stock has seen a 10.04% return over seven days, despite a 10.32% year-to-date decline, driven by long-term momentum. While a narrative suggests the stock is 31.6% undervalued at $137.67, with future growth based on new indications and IP protection, its high P/S ratio of 29.7x raises questions about whether future growth is already priced in.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported stronger-than-expected Q1 financial results, with slimmer losses and higher sales than anticipated. Following these positive results, analysts from Wells Fargo and RBC Capital maintained their "Overweight" and "Outperform" ratings respectively, and slightly increased their price targets for the company's stock. The company's CEO highlighted the successful U.S. launch of IMCIVREE for acquired hypothalamic obesity, with European and Japanese launches anticipated in the coming years.
Rhythm Pharmaceuticals Price Target Raised to $143.00/Share From $140.00 by Canaccord Genuity
Canaccord Genuity has increased its price target for Rhythm Pharmaceuticals (NASDAQ: RYTM) to $143.00 per share, up from $140.00. This adjustment by the analyst firm reflects an updated valuation for the company.
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its Recent Share Price Surge
Rhythm Pharmaceuticals (RYTM) has seen significant share price surges recently, with a 17.6% return in the last week and 49.5% over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is 80.9% undervalued at $96.61, indicating a fair value of around $506.69 per share. However, its Price-to-Sales (P/S) ratio of 30.49x is considerably higher than the biotech industry average, suggesting it might be overvalued based on sales metrics.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) reported a strong Q1 2026, with revenues of $60.1 million, exceeding expectations, and EPS of $-0.83 against an anticipated $-0.86. The company highlighted the successful early launch of IMCIVREE for acquired hypothalamic obesity (HO) in the U.S., with over 150 start forms and positive initial receptivity from prescribers and payers. International expansion is also underway, with European marketing authorization received and an NDA filing in Japan accepted, positioning IMCIVREE for significant growth in the HO market.
Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue Beat - News and Statistics
Rhythm Pharmaceuticals' stock surged nearly 8% after reporting strong first-quarter 2026 earnings, primarily driven by the success of its FDA-approved drug, Imcivree. The company's Q1 revenue of $60.1 million significantly beat analyst estimates and nearly doubled year-over-year, attributed entirely to Imcivree's performance, including a strong start in its newly approved indication for acquired hypothalamic obesity. Despite a GAAP net loss of $0.83 per share, which was slightly better than projections, increased administrative expenses contributed to a deeper loss compared to the previous year.
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Rhythm Pharmaceuticals, Inc. announced that its CEO, David Meeker, M.D., will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026, at 3:00 p.m. PT. The company is a global biopharmaceutical firm focused on rare neuroendocrine diseases, with its lead asset, IMCIVREE® (setmelanotide), approved for treating various forms of obesity. The event will be webcasted and a replay will be available on their investor relations website.
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected Q1 financial results, with narrower losses per share and higher sales than anticipated. Following these results, Wells Fargo and RBC Capital analysts raised their price targets for the company's stock, maintaining Overweight and Outperform ratings, respectively. The company's shares increased by 2.6% after the announcement.
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported strong first-quarter 2026 financial results, with PBS revenues reaching $60 million, driven by increased patient diagnoses and therapy candidates. The company highlighted successful early launch metrics for Insivri in treating acquired hypothalamic obesity (HO) in the US and Europe, alongside positive progress in Japan with anticipated approval by year-end. Rhythm also discussed its pipeline, including upcoming data for Prader-Willi syndrome and plans for a Phase 3 trial with Vivamelagon in HO.
Rhythm Pharmaceuticals to Participate in Bank of America Conference on May 13, 2026
Rhythm Pharmaceuticals is scheduled to participate in the Bank of America Global Healthcare Conference on May 13, 2026. The company's management will hold a fireside chat at 4:20 p.m. Eastern Time, which will be accessible via a live webcast on their Investors & Media website. An archived replay will be available for approximately 30 days after the event.
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Rhythm Pharmaceuticals announced that its Chairman, President, and CEO, David Meeker, M.D., will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13. The company, focused on rare neuroendocrine diseases, will webcast the chat on its investor relations website. Rhythm Pharmaceuticals' lead asset, IMCIVREE® (setmelanotide), is approved for severe obesity associated with specific genetic deficiencies or acquired hypothalamic obesity.
Rhythm CEO to speak at Bank of America healthcare conference May 13
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that its Chairman, President, and CEO, David Meeker, M.D., will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026. The event, taking place at 3:00 p.m. PT in Las Vegas, will be webcast live and a replay will be available for 30 days on the company's Investor Relations site. The company's recent announcements have generally seen positive stock movement, driven by strong IMCIVREE revenue growth and expanded regulatory approvals.
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals reported first-quarter 2026 financial results, with IMCIVREE achieving $60.1 million in global net product revenue and over 150 patient start forms for acquired hypothalamic obesity (HO) in the U.S. following FDA approval. The company also announced European Commission authorization for IMCIVREE in acquired HO and ongoing Japanese regulatory review, with anticipated launches in these regions. Rhythm Pharmaceuticals detailed key business milestones and financial figures, including a net loss of $(56.7) million for the quarter, and provided financial guidance for the full year 2026, estimating Non-GAAP Operating Expenses between $385 million and $415 million.
Rhythm Pharmaceuticals (RYTM) Revenue Ramp With US$201.9m TTM Loss Tests Bullish Narratives
Rhythm Pharmaceuticals (RYTM) recently reported Q1 2026 results, showing a trailing twelve-month revenue of US$189.8 million but a net loss of US$201.9 million. Despite a growing top line, the company's significant losses raise questions about its path to profitability, challenging bullish narratives that rely on strong revenue and earnings growth forecasts. Analysts anticipate a sharp improvement from the current loss position, but the sustained quarterly losses and a high 33.2x P/S multiple against an industry average of 10.8x highlight the risks and the need for clearer signs of margin improvement and cost control.
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss
Rhythm Pharmaceuticals (RYTM) reported a significant increase in net product revenue to $60.1 million in Q1 2026, up from $37.7 million in Q1 2025, driven by strong IMCIVREE sales in both U.S. and international markets. Despite this revenue growth, the company's net loss widened to $55.6 million from $49.5 million in the prior year, primarily due to increased research and development and selling, general, and administrative expenses. As of March 31, 2026, Rhythm Pharmaceuticals held $340.6 million in cash and short-term investments, which management anticipates will fund operations for at least the next 24 months.
Rhythm Pharmaceuticals (Nasdaq:RYTM) - Stock Analysis
Rhythm Pharmaceuticals (RYTM) is a commercial-stage biopharmaceutical company focusing on rare neuroendocrine diseases. The stock is currently trading 79.9% below its estimated fair value, with analysts projecting a 63.73% annual earnings growth and a potential 43.5% increase in stock price. Recent news highlights include new data presentations for Setmelanotide in pediatric patients with acquired hypothalamic obesity and recent FDA approvals for expanded indications of IMCIVREE.
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates
Rhythm Pharmaceuticals, Inc. reported a narrower-than-expected loss in the first quarter, with a loss of $0.94 per share compared to analyst estimates of a $1.02 per share loss. The company also surpassed revenue expectations, bringing in $44.2 million against an anticipated $42.58 million. This positive financial performance indicates potential strength for RYTM in the near term.
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M
Rhythm Pharmaceuticals, Inc. (RYTM) reported first-quarter revenue of $60.1 million, surpassing FactSet's estimated $55.8 million. This financial beat indicates stronger-than-expected performance for the pharmaceutical company.
Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals
Rhythm Pharmaceuticals reported strong Q1 2026 financial results, with IMCIVREE sales reaching $60.1 million, driven by its launch for acquired hypothalamic obesity in the U.S. and European Commission marketing authorization. The company received over 150 patient start forms in the U.S. within six weeks of FDA approval, indicating strong demand. Despite continued net losses of $56.7 million due to commercialization and R&D investments, Rhythm projects sufficient cash to fund operations for at least 24 months.
Rhythm Pharmaceuticals Q1 2026 earnings preview
This article is a placeholder for a Q1 2026 earnings preview for Rhythm Pharmaceuticals. No actual content is present, only the title and publication information.
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals presented new data at the Pediatric Endocrine Society Annual Meeting, highlighting the long-term efficacy of setmelanotide in pediatric patients with acquired hypothalamic obesity (HO). The data showed sustained reductions in BMI and BMI Z-score over 2.5 years, with significant improvements in weight categories after one year of treatment. These findings solidify setmelanotide's role as a treatment for this complex condition, with a safety profile consistent with previous reports.
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals announced new data presentations on setmelanotide in pediatric patients with acquired hypothalamic obesity at the Pediatric Endocrine Society Annual Meeting. Data showed sustained reductions in BMI and BMI-Z, and significant improvements in weight categories after up to 2.5 years of treatment. These findings reinforce setmelanotide's long-term efficacy and safety profile for this patient population.
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)?
Rhythm Pharmaceuticals recently secured expanded marketing authorization in the EU for IMCIVREE to treat hypothalamic obesity, mirroring a prior US FDA approval. This expansion significantly widens the drug's addressable patient population but does not alter the company's reliance on a single commercial asset, its loss-making status, or ongoing capital needs. Investors are encouraged to consider diverse perspectives due to the company's financial profile and the differing fair value estimates from the Simply Wall St community.
Rare obesity trial: 44% of treated children reached healthy or overweight
Rhythm Pharmaceuticals announced new data from pediatric trials of setmelanotide in acquired hypothalamic obesity, presented at the Pediatric Endocrine Society Annual Meeting. The data showed sustained reductions in BMI and BMI Z-score over 2.5 years in a small cohort, and significant improvements in weight categories after 1 year in Phase 3 TRANSCEND trial patients. Notably, 44.4% of treated pediatric patients achieved a healthy or overweight status after one year, with a safety profile consistent with previous reports.
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105
H.C. Wainwright has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its price target at $105. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $131.13. Despite insider selling, major institutions have increased their stakes, and the company beat Q4 revenue estimates. However, Rhythm Pharmaceuticals remains unprofitable and analysts forecast negative EPS for the current year.
Rhythm Pharmaceuticals Receives EC Authorization for First FDA-Approved Treatment of Acquired Hypothalamic Obesity in Europe
Rhythm Pharmaceuticals announced that the European Commission has authorized IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity (HO) in adults and children aged four and older. This marks the first approved treatment for this rare neuroendocrine disease in Europe, following its FDA approval in the United States. The decision is based on positive Phase 3 trial results showing a significant reduction in BMI, with commercial launches in Europe anticipated in 2027.
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC
Jennison Associates LLC significantly increased its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 123.2% in Q4, acquiring over 507,017 shares to reach a total of 918,567 shares valued at approximately $98.3 million. Other major institutions like Vanguard Group Inc. and RA Capital Management L.P. also increased their positions. Despite some insider selling, analysts maintain a "Moderate Buy" consensus with an average target price of $131.13 for Rhythm Pharmaceuticals, which reported a Q4 revenue increase of 36.9% year-over-year.
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide)
Rhythm Pharmaceuticals announced that IMCIVREE® (setmelanotide) has received marketing authorization from the European Commission for the treatment of obesity and control of hunger in adults and children aged 4 and above with acquired hypothalamic obesity (HO). This approval, based on positive results from the Phase 3 TRANSCEND trial, marks the first therapy authorized for acquired HO in Europe. The company plans to work with local health authorities for access across Europe, with commercial launches anticipated in 2027.
Europe authorizes first drug for patients with relentless hunger
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in adults and children aged 4 and above with acquired hypothalamic obesity. This approval is based on positive Phase 3 TRANSCEND trial data showing significant BMI reduction. Commercial launches in Europe are anticipated in 2027, following the U.S. FDA approval for the same indication on March 19, 2026.
Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake
Vanguard Capital Management has filed a Schedule 13G, disclosing a 5.02% beneficial ownership stake in Rhythm Pharmaceuticals Inc. The filing indicates Vanguard beneficially owned 3,432,949 shares of common stock as of March 31, 2026, with sole dispositive power over all these shares and sole voting power over 465,124 shares. This passive investment disclosure suggests institutional ownership rather than an active acquisition attempt, as indicated by the Schedule 13G type.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness
Rhythm Pharmaceuticals (RYTM) has seen recent share price weakness, with declines over the past 1 and 90 days, despite strong long-term performance. The stock's valuation is being assessed against analyst targets and intrinsic estimates, with one narrative suggesting a 40.3% undervaluation based on a fair value of $137.67, driven by potential new indications for setmelanotide. However, ongoing losses and reliance on one drug present clinical and regulatory risks.
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness
Rhythm Pharmaceuticals (RYTM) has experienced recent share price weakness, with a 1-day decline of 2.45% and a 90-day decline of 19.9%. Despite this, the stock shows long-term momentum with a 1-year return of 28.71%. The company's valuation is being assessed, with a "Most Popular Narrative" suggesting it is 40.3% undervalued at $82.12 against a fair value of $137.67, driven by potential regulatory approvals for setmelanotide in new indications.
Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management trimmed its stake in Rhythm Pharmaceuticals (NASDAQ:RYTM) by 10%, selling 68,354 shares. The firm now holds 614,663 shares, representing 0.92% of the company, valued at approximately $66.19 million. Company insiders have also sold 27,267 shares totaling about $2.72 million over the past three months, reducing their collective ownership to 6.10%. Analysts maintain a "Moderate Buy" rating with an average target price of $131.13, following Rhythm's recent earnings beat and 36.9% year-over-year revenue growth.
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing
This article announces an SEC Filing (Form ARS) by RHYTHM PHARMACEUTICALS, INC. (RYTM) on April 29, 2026. The filing is categorized as having a low impact and neutral sentiment, and a PDF document of the filing is available. The article also provides a summary of recent news and SEC filings related to Rhythm Pharmaceuticals.
Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM)
Rhythm Pharmaceuticals (NASDAQ: RYTM) will hold its 2026 Annual Meeting on June 24, 2026, where shareholders will vote on the re-election of two Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory "Say-on-Pay" vote on executive compensation. The company highlights its strong performance in 2025, including significant revenue growth and key clinical milestones, which influenced executive compensation decisions. Rhythm Pharmaceuticals also details its corporate governance, human capital initiatives, and executive compensation philosophy, emphasizing alignment with shareholder interests.
